A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells

Takao Hayakawa, Takashi Aoi, Akihiro Umezawa, Keiya Ozawa, Yoji Sato, Yoshiki Sawa, Akifumi Matsuyama, Shinya Yamanaka, Masayuki Yamato

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To make sure that novel human cell-based products contribute to human health care, it is essential that, based on sound science at present, suitable measures be taken by the manufacturers and regulatory authorities on applying these products to the treatment of patients by taking into account specificity of starting cell lines, the manufacturing process, products, administration procedures, diseases in question, and patient population. As part of such an endeavor, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from autologous human somatic stem cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-2, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan on September 7, 2012. The present paper describes the background information and the development of our study and the resulting guidance. For products derived from autologous somatic stem cells, major points to consider include 1) multipotency and self-replication ability of autologous human somatic stem cells and differences in cell characteristics of the final products from those of the starting cells; 2) a donor's infectious status; 3) the risk of proliferation/reactivation of viruses during the manufacturing processes; 4) robust process control to minimize unevenness of “custom-made” products; 5) a limited amount of samples for quality evaluation of products; and 6) robust application and function of the final products in a cell environment different from where the original cells were localized and were performing their natural endogenous functions. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients.

Original languageEnglish
Pages (from-to)57-69
Number of pages13
JournalRegenerative Therapy
Volume2
DOIs
Publication statusPublished - 01-12-2015

Fingerprint

Equipment Safety
Adult Stem Cells
Stem cells
Drug products
Processing
Pharmaceutical Preparations
Cells
Food safety
Viruses
Health care
Food Safety
Process control
Ethics
Health
Acoustic waves
Personnel
Japan
Stem Cells
Tissue Donors
Guidelines

All Science Journal Classification (ASJC) codes

  • Biomaterials
  • Biomedical Engineering
  • Developmental Biology

Cite this

Hayakawa, Takao ; Aoi, Takashi ; Umezawa, Akihiro ; Ozawa, Keiya ; Sato, Yoji ; Sawa, Yoshiki ; Matsuyama, Akifumi ; Yamanaka, Shinya ; Yamato, Masayuki. / A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. In: Regenerative Therapy. 2015 ; Vol. 2. pp. 57-69.
@article{3dd18baa95114aefb14fd002ba8abc70,
title = "A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells",
abstract = "To make sure that novel human cell-based products contribute to human health care, it is essential that, based on sound science at present, suitable measures be taken by the manufacturers and regulatory authorities on applying these products to the treatment of patients by taking into account specificity of starting cell lines, the manufacturing process, products, administration procedures, diseases in question, and patient population. As part of such an endeavor, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from autologous human somatic stem cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-2, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan on September 7, 2012. The present paper describes the background information and the development of our study and the resulting guidance. For products derived from autologous somatic stem cells, major points to consider include 1) multipotency and self-replication ability of autologous human somatic stem cells and differences in cell characteristics of the final products from those of the starting cells; 2) a donor's infectious status; 3) the risk of proliferation/reactivation of viruses during the manufacturing processes; 4) robust process control to minimize unevenness of “custom-made” products; 5) a limited amount of samples for quality evaluation of products; and 6) robust application and function of the final products in a cell environment different from where the original cells were localized and were performing their natural endogenous functions. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients.",
author = "Takao Hayakawa and Takashi Aoi and Akihiro Umezawa and Keiya Ozawa and Yoji Sato and Yoshiki Sawa and Akifumi Matsuyama and Shinya Yamanaka and Masayuki Yamato",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.reth.2015.05.002",
language = "English",
volume = "2",
pages = "57--69",
journal = "Regenerative Therapy",
issn = "2352-3204",
publisher = "Japanese Society of Regenerative Medicine",

}

A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. / Hayakawa, Takao; Aoi, Takashi; Umezawa, Akihiro; Ozawa, Keiya; Sato, Yoji; Sawa, Yoshiki; Matsuyama, Akifumi; Yamanaka, Shinya; Yamato, Masayuki.

In: Regenerative Therapy, Vol. 2, 01.12.2015, p. 57-69.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells

AU - Hayakawa, Takao

AU - Aoi, Takashi

AU - Umezawa, Akihiro

AU - Ozawa, Keiya

AU - Sato, Yoji

AU - Sawa, Yoshiki

AU - Matsuyama, Akifumi

AU - Yamanaka, Shinya

AU - Yamato, Masayuki

PY - 2015/12/1

Y1 - 2015/12/1

N2 - To make sure that novel human cell-based products contribute to human health care, it is essential that, based on sound science at present, suitable measures be taken by the manufacturers and regulatory authorities on applying these products to the treatment of patients by taking into account specificity of starting cell lines, the manufacturing process, products, administration procedures, diseases in question, and patient population. As part of such an endeavor, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from autologous human somatic stem cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-2, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan on September 7, 2012. The present paper describes the background information and the development of our study and the resulting guidance. For products derived from autologous somatic stem cells, major points to consider include 1) multipotency and self-replication ability of autologous human somatic stem cells and differences in cell characteristics of the final products from those of the starting cells; 2) a donor's infectious status; 3) the risk of proliferation/reactivation of viruses during the manufacturing processes; 4) robust process control to minimize unevenness of “custom-made” products; 5) a limited amount of samples for quality evaluation of products; and 6) robust application and function of the final products in a cell environment different from where the original cells were localized and were performing their natural endogenous functions. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients.

AB - To make sure that novel human cell-based products contribute to human health care, it is essential that, based on sound science at present, suitable measures be taken by the manufacturers and regulatory authorities on applying these products to the treatment of patients by taking into account specificity of starting cell lines, the manufacturing process, products, administration procedures, diseases in question, and patient population. As part of such an endeavor, we studied scientific principles, concepts, and basic technical elements to ensure the quality and safety of therapeutic products derived from autologous human somatic stem cells, taking into consideration scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the development of the Japanese official Notification No. 0907-2, “Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan on September 7, 2012. The present paper describes the background information and the development of our study and the resulting guidance. For products derived from autologous somatic stem cells, major points to consider include 1) multipotency and self-replication ability of autologous human somatic stem cells and differences in cell characteristics of the final products from those of the starting cells; 2) a donor's infectious status; 3) the risk of proliferation/reactivation of viruses during the manufacturing processes; 4) robust process control to minimize unevenness of “custom-made” products; 5) a limited amount of samples for quality evaluation of products; and 6) robust application and function of the final products in a cell environment different from where the original cells were localized and were performing their natural endogenous functions. The ultimate goal of this guidance is to provide suitable medical opportunities as soon as possible to the patients.

UR - http://www.scopus.com/inward/record.url?scp=85045291571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045291571&partnerID=8YFLogxK

U2 - 10.1016/j.reth.2015.05.002

DO - 10.1016/j.reth.2015.05.002

M3 - Article

VL - 2

SP - 57

EP - 69

JO - Regenerative Therapy

JF - Regenerative Therapy

SN - 2352-3204

ER -